Please login to the form below

ribociclib

This page shows the latest ribociclib news and features for those working in and with pharma, biotech and healthcare.

FDA backs earlier use of Lilly’s breast cancer drug Verzenio

year and is predicted to become a $6bn product at peak by EvaluatePharma - as well as Novartis’second-to-market CDK4/6 inhibitor Kisqali (ribociclib)).

Latest news

Novartis bags new breakthrough status for Kisqali in breast cancer

In the study, giving Kisqali (ribociclib) in combination with tamoxifen or an aromatase inhibitor as initial endocrine-based therapy for women in this group significantly prolonged progression-free survival (PFS) compared
NICE backs two advanced breast cancer drugs after price cuts

The draft guidance for palbociclib and ribociclib means that an estimated 8, 000 women will be eligible to receive the new drugs, which in trials have been shown to slow the ... By postponing disease progression, palbociclib and ribociclib may reduce the
Novartis raises pressure in Pfizer’s Ibrance with new Kisqali data

In the study, women taking Kisqali (ribociclib) on top of hormonal therapy as a first-line intervention had a longer progression-free survival (PFS) than those on hormonal therapy alone, said
Prospects for Lilly’s Verzenio hit by botched lung cancer trial

palbociclib) and Novartis with recently-launched Kisqali (ribociclib), although it reckons Verzenio can still lead in breast cancer after picking up an early approval from the FDA towards the end of
Lilly gets early US approval for Ibrance rival abemaciclib

It is the third CDK 4/6 inhibitor to reach the market after Pfizer’s blockbuster Ibrance (palbociclib) - which reached the market in 2015 - and Kisqali (ribociclib) from Novartis which made

More from news
Approximately 4 fully matching, plus 20 partially matching documents found.

Latest appointments

Ipsen boosts specialty care and R&D leadership teams

East. Most recently, Semerjian served as senior vice president and global launch head of ribociclib.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Senior Account Manager or AD - Medical Communications: Salary TBC

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Scientific Director: Great salary and bebefits

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Senior Programme Executive: Salary TBC

Account Manager – Med Comms – London: Salary TBC

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Senior Medical Writer: Great salary and benefits

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Senior Medical Writer: Great salary and bebefits

Senior Account Manager / Account Director: Great salary and bebefits

Editorial Director – Medical Education – Oxford: Negotiable

Medical Writer - (London, Brighton or Copenhagen): Competitive

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Editor – Medical Education Agency – Bucks: Salary TBC

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Senior Account Manager – Med Comms – Kent: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...